Cargando…

Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis

Lipid mediators (LMs) are a unique class of immunoregulatory signalling molecules and known to be affected by frankincense extracts. We performed LM profiling by metabololipidomics in plasma samples from 28 relapsing-remitting multiple sclerosis (RR-MS) patients who took a standardised frankincense...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stürner, Klarissa Hanja, Werz, Oliver, Koeberle, Andreas, Otto, Markus, Pless, Ole, Leypoldt, Frank, Paul, Friedemann, Heesen, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260364/ https://www.ncbi.nlm.nih.gov/pubmed/32472007 http://dx.doi.org/10.1038/s41598-020-65215-6

Ejemplares similares

Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?
por: Stellmann, Jan-Patrick, et al.
Publicado: (2015)

B-cell-depletion reverses dysbiosis of the microbiome in multiple sclerosis patients
por: Troci, Alba, et al.
Publicado: (2022)

Protective Effect of Casperome(®), an Orally Bioavailable Frankincense Extract, on Lipopolysaccharide- Induced Systemic Inflammation in Mice
por: Loeser, Konstantin, et al.
Publicado: (2018)

Is multiple sclerosis progression associated with the HLA-DR15 haplotype?
por: Stürner, Klarissa Hanja, et al.
Publicado: (2019)

Analysis of Boswellic Acid Contents and Related Pharmacological Activities of Frankincense-Based Remedies That Modulate Inflammation
por: Börner, Friedemann, et al.
Publicado: (2021)

Clinical associations and characteristics of the polyspecific intrathecal immune response in elderly patients with non-multiple sclerosis chronic autoimmune-inflammatory neurological diseases – a retrospective cross-sectional study
por: Brauchle, Felix, et al.
Publicado: (2023)

Triterpene Acids from Frankincense and Semi-Synthetic Derivatives That Inhibit 5-Lipoxygenase and Cathepsin G
por: Koeberle, Andreas, et al.
Publicado: (2018)

Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis
por: Paul, Friedemann, et al.
Publicado: (2008)

A case of CLIPPERS syndrome responsive to tocilizumab
por: Rempe, Torge, et al.
Publicado: (2019)

Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial
por: Bellmann-Strobl, Judith, et al.
Publicado: (2021)

Risk knowledge of people with relapsing-remitting multiple sclerosis – Results of an international survey
por: Giordano, Andrea, et al.
Publicado: (2018)

Development of Cortical Lesion Volumes on Double Inversion Recovery MRI in Patients With Relapse-Onset Multiple Sclerosis
por: Faizy, Tobias D., et al.
Publicado: (2019)

Functional and structural connectivity substrates of cognitive performance in relapsing remitting multiple sclerosis with mild disability
por: Has Silemek, Arzu Ceylan, et al.
Publicado: (2020)

Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring
por: Stoessel, Daniel, et al.
Publicado: (2018)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Real‐life long‐term effectiveness of fingolimod in Swiss patients with relapsing‐remitting multiple sclerosis
por: Zecca, C., et al.
Publicado: (2018)

Correction: Increased Perfusion in Normal Appearing White Matter in High Inflammatory Multiple Sclerosis Patients
por: Bester, Maxim, et al.
Publicado: (2015)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

Reassessment of Blood Gene Expression Markers for the Prognosis of Relapsing-Remitting Multiple Sclerosis
por: Hecker, Michael, et al.
Publicado: (2011)

Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period
por: Faizy, Tobias Djamsched, et al.
Publicado: (2017)

Fluctuations of spontaneous EEG topographies predict disease state in relapsing-remitting multiple sclerosis
por: Gschwind, Markus, et al.
Publicado: (2016)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
por: Guarnera, Cristina, et al.
Publicado: (2017)

Frankincense: systematic review
por: Ernst, E
Publicado: (2008)

Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial
por: Rosche, Berit, et al.
Publicado: (2013)

Heterogeneity of multiple sclerosis lesions in fast diffusional kurtosis imaging
por: Thaler, Christian, et al.
Publicado: (2021)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
por: Romme Christensen, Jeppe, et al.
Publicado: (2012)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Defective structural RNA processing in relapsing-remitting multiple sclerosis
por: Spurlock, Charles F, et al.
Publicado: (2015)

Thalamic–hippocampal–prefrontal disruption in relapsing–remitting multiple sclerosis
por: Kern, Kyle C., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b7rdael0227vi0759hsffc7a0k